SIEN - Sientra, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.30
+0.15 (+2.44%)
As of 3:56PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close6.15
Open6.15
Bid6.25 x 800
Ask6.25 x 2200
Day's Range6.00 - 6.30
52 Week Range5.00 - 26.79
Volume899,395
Avg. Volume939,950
Market Cap310.059M
Beta (3Y Monthly)1.75
PE Ratio (TTM)N/A
EPS (TTM)-3.23
Earnings DateMay 4, 2017 - May 8, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.50
Trade prices are not sourced from all markets
  • Here’s What Hedge Funds Think About Sientra Inc (SIEN)
    Insider Monkey21 days ago

    Here’s What Hedge Funds Think About Sientra Inc (SIEN)

    Insider Monkey has processed numerous 13F filings of hedge funds and successful investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find write-ups about an individual hedge fund's trades on numerous financial news […]

  • PR Newswire26 days ago

    Bowes Dermatology by Riverchase is One of First Locations to Offer New miraDry

    MIAMI, June 21, 2019 /PRNewswire/ -- Bowes Dermatology by Riverchase is pleased to announce the launch of breakthrough technology, miraDry. Bowes Dermatology by Riverchase is one of the first locations in the area to provide miraDry, which is clinically proven to eliminate sweat and odor glands. The miraDry system's unique miraWave™ technology delivers precise microwave energy at the dermal-fat interface, to safely heat and destroy sweat and odor glands and hair follicles.

  • What Type Of Shareholder Owns Sientra, Inc.'s (NASDAQ:SIEN)?
    Simply Wall St.28 days ago

    What Type Of Shareholder Owns Sientra, Inc.'s (NASDAQ:SIEN)?

    If you want to know who really controls Sientra, Inc. (NASDAQ:SIEN), then you'll have to look at the makeup of its...

  • Zackslast month

    Stocks Take Another Small Step Back

    Stocks Take Another Small Step Back

  • GlobeNewswirelast month

    Sientra, Inc. Closes $115 Million Public Offering of Common Stock and Exercise of Underwriters’ Option to Purchase Additional Shares

    Sientra, Inc. (SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced the closing of its previously announced underwritten public offering of 17,391,305 shares of its common stock, as well as 2,608,695  additional shares of its common stock pursuant to the full exercise of the option granted to the underwriters. The shares were sold at the public offering price of $5.75 per share and the company estimates the aggregate net proceeds to the company will be approximately $108.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses. Sientra intends to use the net proceeds from this offering to implement sales and marketing initiatives, expand its U.S. and global commercial organizations, fund its research and development efforts, and for general corporate purposes, including general and administrative expenses, capital expenditures and general working capital purposes.

  • Benzingalast month

    Wells Fargo Upgrades Sientra After FDA, Financing Concerns Ease

    Shares of Sientra Inc (NASDAQ: SIEN ) have declined about 25 percent since the company reported its first-quarter results on May 8. Meanwhile, the industry backdrop has improved and the near-term financing ...

  • GlobeNewswirelast month

    Sientra Announces Pricing of Upsized Public Offering of Common Stock

    Sientra, Inc. (SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced the upsizing and pricing of its previously announced underwritten public offering. The Company will sell 17,391,305 shares of its common stock at a public offering price of $5.75 per share. The gross proceeds to Sientra, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $100.0 million.

  • GlobeNewswirelast month

    Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sientra, Inc. (SIEN) ( “Sientra” or the “Company”), a medical aesthetics company, today announced that on May 30, 2019, the Compensation Committee of the Company’s Board of Directors approved equity award grants under the Sientra, Inc. Inducement Plan to 17 new employees. The new employees were granted restricted stock units representing a total of 89,067 shares of common stock.

  • GlobeNewswirelast month

    Sientra Commences Public Offering of Common Stock

    Sientra, Inc. (SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced that it has commenced an underwritten public follow-on offering of approximately $75,000,000 of its common stock to be sold by the Company. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to $11,250,000 of additional shares. Sientra intends to use the net proceeds from this offering to implement sales and marketing initiatives, expand its U.S. and global commercial organizations, fund its research and development efforts, and for general corporate purposes, including general and administrative expenses, capital expenditures and general working capital purposes.

  • Sientra (SIEN) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Sientra (SIEN) Q1 2019 Earnings Call Transcript

    SIEN earnings call for the period ending March 31, 2019.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of SIEN earnings conference call or presentation 8-May-19 8:30pm GMT

    Q1 2019 Sientra Inc Earnings Call

  • Associated Press2 months ago

    Sientra: 1Q Earnings Snapshot

    The Santa Barbara, California-based company said it had a loss of 91 cents per share. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...

  • GlobeNewswire2 months ago

    Sientra Reports First Quarter 2019 Financial Results

    First Quarter 2019 Net Sales of $17.6 million, Growth of 20% year over year Provides 2019 Net Sales Outlook of $79 million to $83 million SANTA BARBARA, Calif., May 08, 2019.

  • Sientra (SIEN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks3 months ago

    Sientra (SIEN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Sientra (SIEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Here's Why Sientra's Shares Got a Lift Today
    Motley Fool3 months ago

    Here's Why Sientra's Shares Got a Lift Today

    The FDA approved a design change for the company's Opus breast implants.

  • GlobeNewswire3 months ago

    Sientra to Release First Quarter Financial Results on May 8, 2019

    Sientra, Inc. (SIEN), a medical aesthetics company (“Sientra” or the “Company”), announced today that the Company will release its first quarter 2019 financial results on Wednesday, May 8, 2019 after market close. Sientra will hold a conference call on Wednesday, May 8, 2019 at 4:30 p.m. ET to discuss the results. A press release disclosing the Company's financial results will be distributed at approximately 4:00 p.m. ET that same day.

  • Those Who Purchased Sientra (NASDAQ:SIEN) Shares A Year Ago Have A 32% Loss To Show For It
    Simply Wall St.3 months ago

    Those Who Purchased Sientra (NASDAQ:SIEN) Shares A Year Ago Have A 32% Loss To Show For It

    It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. That downside risk was realized by Sientra, Inc. (NASDAQ:SIE...

  • GlobeNewswire4 months ago

    Sientra® Issues Statement in Response to FDA Post-Approval Study Warning Letter

    Sientra, Inc. (SIEN), a medical aesthetics company (“Sientra" or the “Company”), today announced it has provided an initial response to the U.S. Food and Drug Administration (“FDA”) related to a post-approval study Warning Letter issued on March 19, 2019 and will provide a comprehensive plan for compliance to FDA within 15 days.

  • Reuters4 months ago

    J&J and Sientra get FDA warning letters over breast implants

    The U.S. Food and Drug Administration has issued warning letters to Sientra Inc and a Johnson & Johnson unit for failing to comply with the post-approval study requirements for their breast implants. Last month, the FDA issued a statement https://www.fda.gov/MedicalDevices/Safety/LetterstoHealthCareProviders/ucm630863.htm warning doctors about a type of lymphoma linked to breast implants after receiving reports of the disease. The agency's letters http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20190319:nPn7rwbQSa, dated March 18, highlighted issues in the companies' post-approval studies, which included evaluating the long-term performance and safety of the implants, used for breast augmentation and reconstruction procedures.

  • Read This Before Selling Sientra, Inc. (NASDAQ:SIEN) Shares
    Simply Wall St.4 months ago

    Read This Before Selling Sientra, Inc. (NASDAQ:SIEN) Shares

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insidersRead More...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of SIEN earnings conference call or presentation 12-Mar-19 8:30pm GMT

    Q4 2018 Sientra Inc Earnings Call

  • Associated Press4 months ago

    Vera Bradley and Guardant Health surge while Express falls

    Stocks that moved substantially or traded heavily on Wednesday: Rite Aid Corp., up 4 cents to 72 cents The drugstore chain purged its top management, including CEO John Stanley, and said it will cut 400 ...

  • Here's Why Sientra Stock Is Plummeting Today
    Motley Fool4 months ago

    Here's Why Sientra Stock Is Plummeting Today

    Investors are worried about the aesthetics company's profitability.

  • TheStreet.com4 months ago

    Sientra Plunges After Posting Wider-Than-Expected Loss

    , a plastic surgery product maker, were falling hard Wednesday after the company reported a wider-than-expected fourth-quarter loss. Sientra lost 87 cents a share in the quarter, wider than analysts' calls for a loss of 67 cents. The company has missed earnings estimates in the last four quarters.